Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01668 |
| Species: | Homo sapiens |
| Position : | chr7:54956710-55086709 |
| Year: | 2019 |
| Title: | Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | glioblastoma |
| PMID: | 31761532 |
| MONDO: | MONDO:0018177 |
| Tissue: | brain |
| Tissue Ontology ID: | UBERON:0000955 |
| Cell Source: | GSC23 |
| CVCL ID: | CVCL_DR59 |
| Cell Type: | glioblastoma stem-like cell |
| Experiment Type: | Enhancer functional perturbation; chromatin-interaction assay; ecDNA regulatory analysis |
| High Throughput Method: | H3K27ac ChIP-seq; ATAC-seq; POLR2A ChIP-seq; RNA-seq; CRISPRi screen; 4C-seq |
| Low Throughput Method: | CRISPRi validation; RT-qPCR; cell-fitness assay; FISH |
| Target gene : | EGFR |
| TF name : | SOX2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| SOX2 | Deactivation of the beta-catenin transactivating complex | reactome | 42 |
| SOX2 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | reactome | 13 |
| SOX2 | POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | reactome | 10 |
| SOX2 | Transcriptional regulation of pluripotent stem cells | reactome | 28 |
| SOX2 | Hs_Endoderm_Differentiation_WP2853_88152 | wikipathways | 62 |
| SOX2 | Hs_Dopaminergic_Neurogenesis_WP2855_87239 | wikipathways | 19 |
| SOX2 | Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 | wikipathways | 12 |
| SOX2 | Hs_Mesodermal_Commitment_Pathway_WP2857_87780 | wikipathways | 47 |
| SOX2 | Hs_Ectoderm_Differentiation_WP2858_89329 | wikipathways | 56 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_01667 | chr7:54956710-55086709 | brain | glioblastoma stem-like cell | glioblastoma |